Mesenchymal stem cells therapy ameliorates esophageal dysmotility in gastroesophageal reflux disease by modulating smooth muscle contractility, alleviating senescence by targeting the DNMT3a-HIF1α axis

doi:10.4252/wjsc.120831

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

(4)

(0)

(45)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Stem Cells. Aug 26, 2026; 18(8): 120831
Published online Aug 26, 2026. doi: 10.4252/wjsc.120831

Full Size Figure Download Figure

Figure 4 Mesenchymal stem cells modulate on channels in gastroesophageal reflux disease rat esophagus. This figure demonstrates the modulation of ion channels by mesenchymal stem cells in gastroesophageal reflux disease rat esophagus. A: Western blot images for anoctamin 1 and calcium voltage-gated channel subunit alpha1 C; B: Immunofluorescence staining images for anoctamin 1 and calcium voltage-gated channel subunit alpha1 C. Error bars represent SEM. ^cP < 0.001 for gastroesophageal reflux disease group vs normal group; ^fP < 0.001 for mesenchymal stem cell group vs gastroesophageal reflux disease group. NS: Not significant; Nor: Normal; GERD: Gastroesophageal reflux disease; MSC: Mesenchymal stem cell; ANO1: Anoctamin 1; CACNA1C: Calcium voltage-gated channel subunit alpha1 C.

Citation: Li Y, Zhu WY, Zhang B, Wang ZR, Chen ZY, Chen QQ, Linghu EQ. Mesenchymal stem cells therapy ameliorates esophageal dysmotility in gastroesophageal reflux disease by modulating smooth muscle contractility, alleviating senescence by targeting the DNMT3a-HIF1α axis. World J Stem Cells 2026; 18(8): 120831
URL: https://www.wjgnet.com/1948-0210/full/v18/i8/120831.htm
DOI: https://dx.doi.org/10.4252/wjsc.120831

Li Y, Zhu WY, Zhang B, Wang ZR, Chen ZY, Chen QQ, Linghu EQ. Mesenchymal stem cells therapy ameliorates esophageal dysmotility in gastroesophageal reflux disease by modulating smooth muscle contractility, alleviating senescence by targeting the DNMT3a-HIF1α axis. World J Stem Cells 2026; 18(8): 120831 [DOI: 10.4252/wjsc.120831]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.